Company attributes
Location
B2X
Pitchbook URL
Legal Name
Rigontec GmbH
Parent Organization
Legal classification
Number of Employees (Ranges)
11 – 50
Full Address
Izb, Am Klopferspitz 19 Planegg/Martinsried 82152 Munich Germany
Investors
Founded Date
January 1, 2014
Email Address
info@rigontec.com
Phone Number
+498920006640
Total Funding Amount (USD)
35,835,000
Latest Funding Round Date
September 6, 2016
Former CEO
Acquisition Transaction
Latest Funding Type
Patents Assigned (Count)
1
Other attributes
Company Operating Status
Closed
Rigontec GmbH is a biotechnology company that develops technology for accessing the retonoic acid-inducible gene pathway, part of the innate immune system, as an approach in cancer immunotherapy to induce both immediate and long-term anti-tumor immunity. The company was acquired by Merck in 2017.
Timeline
No Timeline data yet.
Funding Rounds
Products
Acquisitions
SBIR/STTR Awards
Patents
Further Resources
No Further Resources data yet.